2023 World Conference on Lung Cancer (Posters)-EP09.02. Stereotactic Body Radiotherapy Synergizes Immunotherapy in Advanced or Recurrent NSCLC: A Single-center Experience

EP09.02. Stereotactic Body Radiotherapy Synergizes Immunotherapy in Advanced or Recurrent NSCLC: A Single-center Experience - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to assess the impact of stereotactic body radiotherapy (SBRT) in combination with immune checkpoint inhibitors (ICI) on advanced or recurrent non-small cell lung cancer (NSCLC). The researchers collected data on patients who received SBRT concurrently with ICI between January 2017 and December 2021. The patients were divided into two groups based on the timing of SBRT delivery. Group 1 received SBRT initially or to residual tumors during the first or later-line ICI treatment, while Group 2 received SBRT to progressed tumors regardless of the ICI treatment line. The researchers evaluated progression-free survival (PFS) and overall survival (OS) for all patients and for each group separately. <br /><br />A total of 150 patients were included in the study. The median PFS was 14.3 months, and the median OS was 52.8 months. In Group 1, the median PFS was 20.3 months, and the median OS was not reached. In Group 2, the median PFS was 8.0 months, and the median OS was 30.6 months. <br /><br />The results suggest that SBRT combined with ICI demonstrated favorable survival outcomes for advanced or recurrent NSCLC. Moreover, the researchers found that SBRT performed in a controlled-disease situation, such as delivering SBRT initially or to residual tumors during ICI treatment, had a more promising outcome compared to salvage-intent SBRT delivered to progressing diseases. <br /><br />The study highlights the potential benefit of combining SBRT with ICI in NSCLC treatment. Further research is needed to determine the optimal timing of combining the two therapies and to improve the effectiveness of combination therapy.

Asset Subtitle

Dan Yao

Meta Tag

Speaker Dan Yao

Topic Metastatic NSCLC: Local Therapies - Integration With Systemic Therapies

Keywords

stereotactic body radiotherapy

SBRT

immune checkpoint inhibitors

ICI

non-small cell lung cancer

NSCLC

progression-free survival

PFS

overall survival